This study focuses on individuals diagnosed with new-onset Type 1 Diabetes, an autoimmune condition where the body’s immune system attacks the cells in the pancreas that produce insulin. The research aims to evaluate the effectiveness and safety of combining two different treatments. One treatment is Ladarixin, which is an oral medication taken in capsule form. The other is Antithymocyte Globulin, which is administered through an infusion, a process where medication is delivered directly into a vein.

Participants in the study will be assigned to different groups to receive either the combination of both medications or Antithymocyte Globulin along with a placebo. During the course of the study, changes in the body’s ability to produce insulin will be monitored. This is measured by looking at levels of C-peptide, a substance produced by the body when insulin is made, often following a Mixed Meal Tolerance Test, which is a procedure used to see how the body reacts to consuming a meal.